Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27872610 | 0.89 | TP53 (0.59) | ALDH1A1SMN1; SMN2CA1CA2CYP1A2 | |
| SCHEMBL2656317 | 0.82 | ADORA3 (0.54) | ALDH1A1SMN1; SMN2CA1CA2CA12 | |
| SCHEMBL11304280 | 0.77 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2CYP2C9CA1CA2 | |
| SCHEMBL14424458 | 0.77 | MARS1 (0.58) | ALDH1A1SMN1; SMN2RAB9ALMNANPC1 | |
| SCHEMBL2183716 | 0.77 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2HPGDKDM4EMAPT | |
| SCHEMBL14424482 | 0.76 | EPHX1 (0.63) | ALDH1A1RAB9ANPC1MAPTKMT2A | |
| SCHEMBL934619 | 0.76 | HPGD (0.59) | ALDH1A1HPGDKDM4EMEN1POLB | |
| SCHEMBL27656176 | 0.76 | RAB9A (0.58) | ALDH1A1SMN1; SMN2CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL5537059 | 0.75 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2CYP2C9CA1CA2 | |
| SCHEMBL13973086 | 0.75 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2CYP2C9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-1888592-B1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-04-06 | — | — | EP | disclosed |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-02-10 | — | — | US | disclosed |
| US-7799798-B2 | Spiroheterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-09-21 | — | — | US | disclosed |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-05-01 | — | — | US | disclosed |
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| US-20060252758-A1 | Spiroheterocyclic compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258659-A1 | Heterocyclic compounds and their uses as therapeutic agents | TRPV1, TRPV3, TRPV5 | ALDH1A1 807/4885SMN1; SMN2 295/4885CYP2C9 1739/4885 |
| US-20060252758-A1 | Spiroheterocyclic compounds and their uses as therapeutic agents | SCN3A, SCN1B, SCN2B | ALDH1A1 1435/4885SMN1; SMN2 1399/4885CYP2C9 1179/4885 |
| US-20080103151-A9 | Heterocyclic compounds and their uses as therapeutic agents | TRPV1, TRPV3, TRPV5 | ALDH1A1 807/4885SMN1; SMN2 295/4885CYP2C9 1739/4885 |
| US-20110034500-A1 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | ALDH1A1 1200/4885SMN1; SMN2 1253/4885CYP2C9 919/4885 |
| US-20120035199-A9 | SPIROHETEROCYCLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | SCN3A, SCN1B, SCN2B | ALDH1A1 1200/4885SMN1; SMN2 1253/4885CYP2C9 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.